Han Ken-Ryu, Janzen Nicolette K, McWhorter Valerie C, Kim Hyung L, Pantuck Allan J, Zisman Amnon, Figlin Robert A, Dorey Frederick J, Said Jonathan W, Belldegrun Arie S
UCLA Department of Urology, Los Angeles, CA, USA.
Urol Oncol. 2004 Sep-Oct;22(5):410-4. doi: 10.1016/S1078-1439(03)00173-X.
The purpose of the study was to evaluate unilocular and multilocular cystic renal cell carcinoma (cRCC). These tumors are a rare entity, comprising approximately 1 to 2% of all renal tumors, and their true biologic behavior is not well-known. Initial review of renal cell carcinoma (RCC) cases treated at our institution between 1989 and 2001 identified 39 cases of cRCC. However, histopathologic review of these cases by 2 pathologists revealed that only 18 cases met the criteria that all tumors have a cystic component that constitutes at least 75% of the total lesion without evidence of necrosis. These cases were compared to 614 conventional clear cell RCC cases with regards to clinical outcomes. All 18 patients presented with localized (N0M0) disease. Thirteen (72%) of the tumors were Fuhrman Grade 1, while the remaining 5 (28%) were Fuhrman Grade 2. By comparison, only 60% of the clear cell RCC tumors were Grade 1 or 2. Similarly, 83% of cRCC were pT1 tumors compared to only 35% of conventional clear cell tumors. Mean tumor size for the cRCC tumors was 4.9 cm compared to 7.4 cm for conventional clear cell tumors. Cystic RCC patients had an 82% four-year disease-specific survival (DSS). Unilocular and multilocular cRCC is a distinct subtype of clear cell RCC. Its biology appears to be more favorable with regards to important prognostic factors such as metastatic presentation, Fuhrman grade, 1997 T stage, and tumor size. These findings suggest that cRCC patients may benefit from nephron sparing surgery.
本研究的目的是评估单房性和多房性囊性肾细胞癌(cRCC)。这些肿瘤是一种罕见的实体,约占所有肾肿瘤的1%至2%,其真正的生物学行为尚不为人所知。对1989年至2001年在我们机构接受治疗的肾细胞癌(RCC)病例进行初步审查,确定了39例cRCC。然而,两位病理学家对这些病例进行组织病理学审查后发现,只有18例符合所有肿瘤都有一个囊性成分,该成分至少占总病变的75%且无坏死证据的标准。将这些病例与614例传统透明细胞RCC病例的临床结果进行了比较。所有18例患者均表现为局限性(N0M0)疾病。其中13例(72%)肿瘤为福尔曼1级,其余5例(28%)为福尔曼2级。相比之下,透明细胞RCC肿瘤中只有60%为1级或2级。同样,83%的cRCC为pT1肿瘤,而传统透明细胞肿瘤中这一比例仅为35%。cRCC肿瘤的平均大小为4.9厘米,而传统透明细胞肿瘤为7.4厘米。囊性RCC患者的四年疾病特异性生存率(DSS)为82%。单房性和多房性cRCC是透明细胞RCC的一种独特亚型。就转移表现、福尔曼分级、1997年T分期和肿瘤大小等重要预后因素而言,其生物学行为似乎更有利。这些发现表明,cRCC患者可能从保留肾单位手术中获益。